Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2703-2708

  Trbusek, Martin ^a   Smardova, Jana ^a   Malcikova, Jitka ^a   Sebejova, Ludmila ^a   Dobes, Petr ^a   Svitakova, Miluse ^a   Vranova, Vladimira ^a   Mraz, Marek ^a   Francova, Hana Skuhrova ^a   Doubek, Michael ^a   Brychtova, Yvona ^a   Kuglik, Petr ^a   Pospisilova, Sarka ^a   Mayer, Jiri ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA BINDING MOTIF; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUNCTION TEST; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEFECT;

ADOLESCENT; ADULT; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; PROGNOSIS; PROTEIN BINDING; TIME FACTORS;

EID: 79960116871     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.7872     Document Type: Article

References (37)

1. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
2. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
3. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
4. Döhner H, Fisher K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy in chronic B-cell leukemia. Blood 85:1580-1589, 1995
5. Stilgenbauer S, Bullinger L, Lichter P, et al: Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16:993-1007, 2002 (Pubitemid 34618838)
6. Malcikova J, Smardova J, Rocnova L, et al: Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: Selection, impact on survival and response to DNA-damage. Blood 114:5307-5314, 2009
7. Zenz T, Krober A, Scherer K, et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329, 2008
8. Rossi D, Cerri M, Deambrogi C, et al: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 15:995-1004, 2009
9. Dicker F, Herholz H, Schnittger S, et al: The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117-124, 2009
10. Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479, 2010
11. Zenz T, Habe S, Denzel T, et al: Detailed analysis of p53 pathway defects in fludarabinerefractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589-2597, 2009
12. Badoux XC, Keating MJ, Wierda WG: What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep 6:36-46, 2011
13. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
14. Berns EM, van Staveren IL, Look MP, et al: Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77:1130-1136, 1998 (Pubitemid 28116285)
15. Young KH, Leroy K, Moller MB, et al: Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study. Blood 112:3088-3098, 2008
16. Zenz T, Vollmer D, Trbusek M, et al: TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 24:2072-2079, 2010
17. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355, 1994 (Pubitemid 24259959)
18. Dittmer D, Pati S, Zambetti G, et al: Gain of function mutations in p53. Nat Genet 4:42-46, 1993 (Pubitemid 23165910)
19. Oren M, Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2:a001107, 2010
20. Weisz L, Damalas A, Liontos M, et al: Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor α in cancer cells. Cancer Res 67:2396-2401, 2007 (Pubitemid 46548921)
21. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462, 1992
22. Mimeault M, Hauke R, Batra SK: Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-691, 2008 (Pubitemid 351559599)
23. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
24. Flaman JM, Frebourg T, Moreau V, et al: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92:3963-3967, 1995
25. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629, 2007 (Pubitemid 46744292)
26. Best OG, Gardiner AC, Davis ZA, et al: A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 23:212-214, 2009
27. Tam CS, Shanafelt TD, Wierda WG, et al: De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience. Blood 114:957-964, 2009
28. Lin TS: New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 5:29-34, 2010
29. Blagosklonny MV: p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 14:1901-1907, 2000
30. Gurtner A, Starace G, Norelli G, et al: Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain-of-function. J Biol Chem 285:14160-14169, 2010
31. Ringshausen I, Dechow T, Schneller F, et al: Constitutive activation of MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 18:1964-1970, 2004
32. Dicker F, Kater AP, Prada CE, et al: CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 108:3450-3457, 2006
33. Wierda WG, Castro JE, Aguillon R, et al: A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 24:1893-1900, 2010
34. Alonso R, Lopez-Guerra M, Upshaw R, et al: Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 114:1563-1575, 2009
35. Olivier M, Langerod A, Carrieri, et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167, 2006
36. Resnick MA, Inga A: Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A 100:9934-9939, 2003 (Pubitemid 37087046)
37. Mraz M, Pospisilova S, Malinova K, et al: MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 50:506-509, 2009